Related Experiment Video
Updated: Mar 27, 2026
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
Epidermal growth factor receptor targeting and challenges in glioblastoma
Amy Haseley Thorne1, Ciro Zanca1, Frank Furnari1
1Ludwig Institute for Cancer Research, University of California at San Diego, La Jolla, California (A.H.T., C.Z., F.F.); Moores Cancer Center, University of California at San Diego, La Jolla, California (F.F.); Department of Pathology, University of California at San Diego, La Jolla, California (F.F.).
Abstract:
With the evolution of technology, there is now a deeper understanding of glioblastoma as an inter- and intraheterogeneous disease comprising a multitude of genetically and epigenetically different cancer cells. Greater characterization of glioblastoma at the molecular level has improved its initial pathophysiological staging and classification. With this knowledge comes the hope that more efficacious therapies to combat this highly lethal disease are on the horizon. One possibility for intervention is represented by the targeting of epidermal growth factor receptor (EGFR), which is amplified and mutated in a large subset of patients. In this review, we provide a brief overview of EGFR and its mutated form, EGFR variant III, describing the downstream cellular pathways activated by each receptor, available animal models, therapeutic strategies to inhibit the receptor, and possible intervention routes to efficiently target this receptor and prevent the emergence of resistant mechanisms which to date have hampered a successful therapeutic outcome.
Insights
Glioblastoma is a complex brain tumor with diverse cancer cells. Targeting the epidermal growth factor receptor (EGFR) and its variant (EGFRvIII) offers a promising therapeutic strategy to overcome this lethal disease.
Area of Science:
- Neuro-oncology
- Cancer Biology
- Molecular Medicine
Background:
- Glioblastoma is characterized by significant inter- and intra-tumor heterogeneity at genetic and epigenetic levels.
- Advances in molecular characterization have refined glioblastoma staging and classification.
- The epidermal growth factor receptor (EGFR) is frequently amplified and mutated in glioblastoma patients.
Purpose of the Study:
- To review the role of EGFR and its variant, EGFR variant III (EGFRvIII), in glioblastoma.
- To summarize downstream signaling pathways activated by EGFR and EGFRvIII.
- To discuss current and potential therapeutic strategies targeting EGFR in glioblastoma.
Main Methods:
- Review of existing literature on glioblastoma, EGFR, and EGFRvIII.
- Analysis of downstream cellular pathways activated by EGFR signaling.
- Examination of preclinical animal models for glioblastoma.
- Evaluation of therapeutic strategies and resistance mechanisms.
Main Results:
- EGFR and EGFRvIII activate distinct downstream pathways contributing to glioblastoma progression.
- Various animal models exist for studying glioblastoma and testing EGFR-targeted therapies.
- Therapeutic strategies targeting EGFR are under development, but resistance remains a challenge.
Conclusions:
- Targeting EGFR and its variants represents a key therapeutic avenue for glioblastoma.
- Understanding resistance mechanisms is crucial for developing effective and durable treatment strategies.
- Further research into novel intervention routes is needed to improve patient outcomes.
Related Concept Videos
02:38Mitogens and the Cell Cycle
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...